Genentech Licenses Sangamo’s DNA-Binding Technology For Protein Production
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech and Medarex are the only two firms with commercial licenses for the zinc finger DNA-binding protein technology.
You may also be interested in...
Sangamo Acquisition Of Edwards’ R&D Program Will Enhance Partnering Opportunities
Sangamo will acquire Edwards’ angiogenesis program based on zinc finger protein activation of the VEGF gene.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.